LYEL Quote, Financials, Valuation and Earnings

Cogent Biosciences, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of --. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Cogent Biosciences, Inc.'s return on equity of -117.99%.

Lyell Immunopharma, Inc. has a consensus price target of $19.00, signalling downside risk potential of -14.84%. On the other hand Cogent Biosciences, Inc. has an analysts' consensus of $47.18 which suggests that it could grow by 20.49%. Given that Cogent Biosciences, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Cogent Biosciences, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cogent Biosciences, Inc. has a beta of 0.505, suggesting its less volatile than the S&P 500 by 49.519%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cogent Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Cogent Biosciences, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are larger than Cogent Biosciences, Inc. quarterly revenues of --. Lyell Immunopharma, Inc.'s net income of -$38.8M is higher than Cogent Biosciences, Inc.'s net income of -$80.9M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Cogent Biosciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 80,900.63x versus 55.99x for Cogent Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ionis Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -82.06%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Ionis Pharmaceuticals, Inc.'s return on equity of -43.01%.

Lyell Immunopharma, Inc. has a consensus price target of $19.00, signalling downside risk potential of -14.84%. On the other hand Ionis Pharmaceuticals, Inc. has an analysts' consensus of $85.47 which suggests that it could grow by 4.43%. Given that Ionis Pharmaceuticals, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Ionis Pharmaceuticals, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ionis Pharmaceuticals, Inc. has a beta of 0.296, suggesting its less volatile than the S&P 500 by 70.45%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ionis Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Ionis Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Ionis Pharmaceuticals, Inc. quarterly revenues of $156.7M. Lyell Immunopharma, Inc.'s net income of -$38.8M is higher than Ionis Pharmaceuticals, Inc.'s net income of -$128.6M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Ionis Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 80,900.63x versus 13.93x for Ionis Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -255.85%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Lyell Immunopharma, Inc. has a consensus price target of $19.00, signalling downside risk potential of -14.84%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -19.81%. Given that NovaBay Pharmaceuticals, Inc. has more downside risk than Lyell Immunopharma, Inc., analysts believe Lyell Immunopharma, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 1.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 80,900.63x versus 2.06x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ovid Therapeutics, Inc. has a net margin of -258973.33% compared to Lyell Immunopharma, Inc.'s net margin of -9210.61%. Lyell Immunopharma, Inc.'s return on equity of -86.7% beat Ovid Therapeutics, Inc.'s return on equity of -59.7%.

Lyell Immunopharma, Inc. has a consensus price target of $19.00, signalling downside risk potential of -14.84%. On the other hand Ovid Therapeutics, Inc. has an analysts' consensus of $4.19 which suggests that it could grow by 164.95%. Given that Ovid Therapeutics, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe Ovid Therapeutics, Inc. is more attractive than Lyell Immunopharma, Inc..

Lyell Immunopharma, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ovid Therapeutics, Inc. has a beta of 0.045, suggesting its less volatile than the S&P 500 by 95.453%.

Lyell Immunopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ovid Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lyell Immunopharma, Inc. pays -- of its earnings as a dividend. Ovid Therapeutics, Inc. pays out -- of its earnings as a dividend.

Lyell Immunopharma, Inc. quarterly revenues are $15K, which are smaller than Ovid Therapeutics, Inc. quarterly revenues of $132K. Lyell Immunopharma, Inc.'s net income of -$38.8M is lower than Ovid Therapeutics, Inc.'s net income of -$12.2M. Notably, Lyell Immunopharma, Inc.'s price-to-earnings ratio is -- while Ovid Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lyell Immunopharma, Inc. is 80,900.63x versus 16.99x for Ovid Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.